To further accelerate the validation and clinical application of liquid biopsy-based ccfDNA-targeted NGS assays, SeraCare has developed the Seraseq ctDNA Complete that expands coverage of all relevant variant types including SNVs, INDELs, CNVs, and gene fusions in a single highly-multiplexed reference sample. These new products are offered in either a purified ctDNA format or a plasma-like matrix format, all precisely quantitated by digital PCR against a single well-characterized genomic background (GM24385), and orthogonally validated with NGS technology.
This specific ctDNA Complete product has an allele frequency of 0% wild-type.
25 unique multiplexed variants in 16 genes, covering 12 SNVs, 7 INDELs, 3 CNVs, and 3 SVs, in purified and plasma-like matrix formats.
6 different allele frequencies available: wild-type, 0.1%, 0.5%, 1%, 2.5%, and 5%
Allows end-to-end evaluation of assay performance across the entire workflow, including pre-analytic extraction steps
Variants quantitated with digital PCR and orthogonally validated by NGS
Blends with well-characterized GM24385 human genomic DNA as background wild-type material
Manufactured within cGMP-compliant and ISO 13485-certified facilities.
Archer® is a registered trademark, and Reveal ctDNA™ is a trademark of ArcherDx, Inc. Oncomine® is a registered trademark of Thermo Fisher Scientific. UltraSEEK™ is a trademark of Agena Bioscience, Inc.